Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Subscribe To Our Newsletter & Stay Updated
